MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
Year: 2021
Type: conference-abstract
Authors: Sagar Lonial, Ajay K. Nooka, Praneetha Thulasi, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Douglas Sborov, Brian E. Zaugg, Rakesh Popat, Simona Degli Esposti, January Baron, Allison Doherty, Eric Lewis, Joanna Opalinska, Prani Paka, Trisha Piontek, Ira Gupta, Asim V. Farooq, Andrzej Jakubowiak
Institutions: Winship Cancer Institute, Emory University, Emory Eye Center, University of Maryland, Baltimore, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Huntsman Cancer Institute, University of Utah, University College London Hospitals NHS Foundation Trust, Moorfields Eye Hospital NHS Foundation Trust, NIHR Moorfields Biomedical Research Centre, University College London, GlaxoSmithKline (United States), University of Chicago Medical Center
Language: English
Topic: Drug-Induced Ocular Toxicity
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3197211833